Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids
Journal of Opioid Management · 07.12.2017 · 13 (6) · 379-389
DOI: 10.5055/jom.2017.0416 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Opioid Management, online erschienen am 07.12.2017. Verfasst von Christopher J Miller und 3 weiteren Autor:innen. Beteiligte Einrichtung: 3D Communications, Raleigh, North Carolina. Hauptthemen laut MEDLINE: Abuse-Deterrent Formulations. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
It is the current policy of the US Food and Drug Administration (FDA) to convene expert Advisory Committees to provide input on key regulatory decisions regarding opioid products, including approval and labeling of opioid abuse-deterrent formulations (ADFs). Advisory Committee meetings on ADF opioids consider whether the laboratory and clinical data submitted by the sponsor are sufficient to support marketing approval and labeling of the product with properties expected to deter abuse by specific routes of abuse (ie, oral, intranasal, intravenous). The FDA has typically followed the approval and labeling recommendations for ADFs reviewed by its Advisory Committees, highlighting the importance of these meetings in the regulatory approval process. This review describes common issues considered by Advisory Committees for ADF opioids as well as insights on how to prepare for these meetings based on recent relevant experience and regulatory decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 3D Communications, Raleigh, North Carolina.
- Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, Colorado.
- Analgesic Solutions, Natick, Massachusetts; Adjunct Associate Professor, Department of Anesthesiology, Tufts University School of Medicine, Boston, Massachusetts.
- Vice President of Scientific Affairs, PRA Health Sciences, Salt Lake City, Utah.
Zitieren
APA
Miller, C. J., Dart, R. C., Katz, N. P., & Webster, L. R. (2017). Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids. Journal of Opioid Management, 13(6), 379-389. https://doi.org/10.5055/jom.2017.0416
Vancouver
Miller CJ, Dart RC, Katz NP, Webster LR. Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids. Journal of Opioid Management. 2017;13(6):379-389. doi:10.5055/jom.2017.0416
BibTeX
@article{Miller2017,
author = {Miller, Christopher J and Dart, Richard C and Katz, Nathaniel P and Webster, Lynn R},
title = {Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids},
journal = {Journal of Opioid Management},
year = {2017},
volume = {13},
number = {6},
pages = {379--389},
doi = {10.5055/jom.2017.0416}
}
EUVIMED